CEO Andrew Newland stated that “ANGLE’s first large scale clinical studies of 400 patients have demonstrated positive results with the potential to out-perform current standard of care. This success enables ANGLE to move forward into the validation phase for the use of Parasortix in its first clinical application. We believe ANGLE is building momentum towards securing a leading and well-differentiated commercial position in the emerging multi-billion dollar liquid biopsy market.”
The Parasortix system is designed to help identify women with ovarian cancer and act as a helping hand to existing healthcare analytical platforms. With its undiscovered potential, Parasortix technology may even prove to be valuable in identification of other important cell types and the diagnosis of other forms of cancer in the future.